Abstract:Background: Extracellular aggregation of the amyloid-β (Aβ) peptide into toxic multimers is a key event in Alzheimer's disease (AD) pathogenesis. Aβ aggregation is concentration-dependent, with higher concentrations of Aβ much more likely to form toxic species. The processes that regulate extracellular levels of Aβ therefore stand to directly affect AD pathology onset. Studies from our lab and others have demonstrated that synaptic activity is a critical regulator of Aβ production through both presynaptic and postsynaptic mechanisms. AMPA receptors (AMPA-Rs), as the most abundant ionotropic glutamate receptors, have the potential to greatly impact Aβ levels. Methods: In order to study the role of AMPA-Rs in Aβ regulation, we used in vivo microdialysis in an APP/PS1 mouse model to simultaneously deliver AMPA and other treatments while collecting Aβ from the interstitial fluid (ISF). Changes in Aβ production and clearance along with inflammation were assessed using biochemical approaches. IL-6 deficient mice were utilized to test the role of IL-6 signaling in AMPA-R-mediated regulation of Aβ levels. Results: We found that AMPA-R activation decreases in ISF Aβ levels in a dose-dependent manner. Moreover, the effect of AMPA treatment involves three distinct pathways. Steady-state activity of AMPA-Rs normally promotes higher ISF Aβ. Evoked AMPA-R activity, however, decreases Aβ levels by both stimulating glutamatergic transmission and activating downstream NMDA receptor (NMDA-R) signaling and, with extended AMPA treatment, acting independently of NMDA-Rs. Surprisingly, we found this latter, direct AMPA pathway of Aβ regulation increases Aβ clearance, while Aβ production appears to be largely unaffected. Furthermore, the AMPA-dependent decrease is not observed in IL-6 deficient mice, indicating a role for IL-6 signaling in AMPA-R-mediated Aβ clearance. Conclusion: Though basal levels of AMPA-R activity promote higher levels of ISF Aβ, evoked AMPA-R signaling decreases Aβ through both NMDA-R-dependent and -independent pathways. We find that evoked AMPA-R signaling increases clearance of extracellular Aβ, at least in part through enhanced IL-6 signaling. These data emphasize that Aβ regulation by synaptic activity involves a number of independent pathways that together determine extracellular Aβ levels. Understanding how these pathways maintain Aβ levels prior to AD pathology may provide insights into disease pathogenesis.

Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β.

Inhibition of AMP-Activated Protein Kinase Signaling Alleviates Impairments in Hippocampal Synaptic Plasticity Induced by Amyloid Β

P2‐157: BRAIN‐SPECIFIC REPRESSION OF AMPKα1 ALLEVIATES MEMORY DEFICITS AND SYNAPTIC FAILURE IN A MOUSE MODEL OF ALZHEIMER'S DISEASE

Therapeutic Potential of AMP-Activated Protein Kinase in Alzheimer’s Disease

Brain-specific repression of AMPK1 alleviates pathophysiology in Alzheimer's model mice

Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease

Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer's model mice.

Isoform-specific Effects of Neuronal Inhibition of AMPK Catalytic Subunit on LTD Impairments in a Mouse Model of Alzheimer’s Disease

Isoform-specific effects of neuronal inhibition of AMPK catalytic subunit on LTD impairments in a mouse model of Alzheimer's disease

Suppression of neuronal AMPKβ2 isoform impairs recognition memory and synaptic plasticity

AMPA-ergic regulation of amyloid-β levels in an Alzheimer's disease mouse model

Akt activation ameliorates deficits in hippocampal-dependent memory and activity-dependent synaptic protein synthesis in an Alzheimer’s disease mouse model

Neuronal AMP-activated protein kinase hyper-activation induces synaptic loss by an autophagy-mediated process

Effect of AMPKα2 Knockdown on Alzheimer's Pathogenesis and Cognitive Deficits in Young Tg19959 Mice.

Antagonists Targeting Eef2 Kinase Rescue Multiple Aspects of Pathophysiology in Alzheimer's Disease Model Mice

O3–02–01: Reversal of Synaptic Plasticity and Spatial Memory Deficits in APP/PS1 Mice by Suppressing Protein Kinase GCN2

Isoform-specific dysregulation of AMP-activated protein kinase signaling in a non-human primate model of Alzheimer's disease

Genetic Reduction of Eef2 Kinase Alleviates Pathophysiology in Alzheimer’s Disease Model Mice

AMPK Ameliorates Tau Acetylation and Memory Impairment Through Sirt1

Repression of the eIF2α kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer's disease.

Suppression of the Kinase for Elongation Factor 2 Alleviates Mglur-Ltd Impairments in a Mouse Model of Alzheimer's Disease.